• Mashup Score: 5
    First patient dosed in SAR’514 / IPH6401 Phase 1/2 clinical trial in relapsed/refractory multiple myeloma | Innate Pharma - 11 month(s) ago

    Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) Second molecule from Innate’s multi-specific NK cell engager platform ANKET® to progress to…

    Source: www.innate-pharma.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of MM_Hub
      MM_Hub

      🚨 NEWS 🚨 First patient dosed in a phase I/II clinical trial of SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager, for the treatment of RRMM and RR light-chain amyloidosis. Read more: https://t.co/iUabCcwo7N #mmsm #myeloma #ALamyloidosis #mednews https://t.co/QdKZPPPXcN